Matthew Frankel
Vyne Therapeutics (Israel)(IL)
Publications by Year
Research Areas
Liver Diseases and Immunity, Inflammatory Bowel Disease, Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Antimicrobial Resistance in Staphylococcus
Most-Cited Works
- → Release of protein A from the cell wall of Staphylococcus aureus(2014)145 cited
- → A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis(2007)144 cited
- → Staphylococcus aureus Mutants Lacking the LytR-CpsA-Psr Family of Enzymes Release Cell Wall Teichoic Acids into the Extracellular Medium(2013)111 cited
- → Determinants of Murein Hydrolase Targeting to Cross-wall of Staphylococcus aureus Peptidoglycan(2012)92 cited
- → Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection(2015)91 cited
- → Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis(2010)87 cited
- → LytN, a Murein Hydrolase in the Cross-wall Compartment of Staphylococcus aureus, Is Involved in Proper Bacterial Growth and Envelope Assembly(2011)80 cited
- → Induction of Monocyte Binding to Endothelial Cells by MM-LDL(1999)67 cited
- → SagB Glucosaminidase Is a Determinant of Staphylococcus aureus Glycan Chain Length, Antibiotic Susceptibility, and Protein Secretion(2016)53 cited
- → Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis†(2009)52 cited